With the rapidly evolving regulatory landscape, staying on top of the latest updates is crucial for companies in biopharma and medical devices.

The European Commission approved Johnson and Johnson’s Yuvanci as the first single-pill combination therapy for PAH.

Convincing healthcare providers and patients of Neffy’s reliability during allergic reactions will require extensive ...

Biosimilars have emerged as a significant advancement in the field of rheumatology, offering a new paradigm in the treatment ...

Quality issues were found in several generic drugs by regulatory agencies in Tamil Nadu and Maharashtra. Alerts have been ...

Liposomal Doxorubicin Market Liposomal Doxorubicin Market Dublin, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The "Liposomal ...

Poland is set to receive shipments of COVID-19 vaccines from Latvia in early October, the Polish health minister announced, ...

SIFI, a leading international ophthalmic company, announced that is has received a Notice of Allowance from the European ...

Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...

Swissmedic is expected to decide on the approval of the first new drug for Alzheimer’s disease in two decades. The decision ...